Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Navidea Biopharma (NAVB) Reports Q1 Loss of $0.24
May 8, 2019 5:19 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.24), versus ($0.83) reported last year. Revenue for the quarter came in at $136 thousand, versus $275.65 thousand reported last year.
For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.
... More